Peptides · 2026
Altered gastrointestinal function and neurotensin signaling in experimental type 2 diabetes.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Öztürk Sudenaz, Kum Hilal, Sunuç Şevval, Köse Helin, İleri̇ Meşe Öykü, Kayali Damla Gökçeoğlu, Ülker Gökay, Yüksel Meral, Gören Zafer, Çi̇li̇ngi̇r Kaya Özlem Tuğce, Memi Gülsün, Ozdemir Kumral Zarife Nigar
Аннотация
BACKGROUND: Type 2 diabetes (T2D) often leads to diabetic gastroenteropathy characterized by gastrointestinal motility disorders, mucosal damage, and oxidative stress. Neurotensin (NT), a gastrointestinal peptide, modulates mucosal healing and metabolic regulation, but its role in diabetic GI dysfunction remains unclear.
METHODS: A streptozotocin (STZ) + nicotinamide (NAD) rat model was used to induce a non-obese T2D phenotype. Male Sprague Dawley rats were assigned to four groups (n = 8/group): Control, STZ, STZ + NT, and STZ + NT + SR-48692 (NTR1 antagonist). Systemic metabolic parameters, serum biochemical markers, gastric and ileal histopathology, oxidative stress markers (MDA, GSH, MPO, luminol and lucigenin chemiluminescence), and neurotransmitter levels (dopamine, serotonin, norepinephrine) were evaluated. Gastrointestinal function was assessed by intestinal transit, visceromotor reflex responses, and isolated organ bath analysis of gastric and ileal smooth muscle contractility.
RESULTS: Diabetes induction caused significant hyperglycemia, dyslipidemia, hepatic and renal dysfunction, accompanied by marked gastric and ileal structural injury, including mucosal disruption, reduced glycoprotein content, and altered NT immunoreactivity. These changes were associated with increased oxidative stress, inflammatory activity, and disturbances in monoaminergic signaling. Functionally, diabetic rats exhibited impaired intestinal transit, reduced visceral sensory responses, and diminished cholinergic contractility in gastric and ileal smooth muscle. NT treatment significantly attenuated hyperglycemia, improved serum metabolic abnormalities, restored mucosal architecture, reduced oxidative stress, and improved gastrointestinal motility and contractile function. Most protective effects were abolished by SR-48692 co-administration, supporting a predominantly NTR1-dependent mechanism.
CONCLUSION: NT ameliorates diabetes-induced GI dysfunction and systemic metabolic disturbances primarily via NTR1 signaling, suggesting the NT/NTR1 axis as a potential therapeutic target for diabetic gastroenteropathy.
METHODS: A streptozotocin (STZ) + nicotinamide (NAD) rat model was used to induce a non-obese T2D phenotype. Male Sprague Dawley rats were assigned to four groups (n = 8/group): Control, STZ, STZ + NT, and STZ + NT + SR-48692 (NTR1 antagonist). Systemic metabolic parameters, serum biochemical markers, gastric and ileal histopathology, oxidative stress markers (MDA, GSH, MPO, luminol and lucigenin chemiluminescence), and neurotransmitter levels (dopamine, serotonin, norepinephrine) were evaluated. Gastrointestinal function was assessed by intestinal transit, visceromotor reflex responses, and isolated organ bath analysis of gastric and ileal smooth muscle contractility.
RESULTS: Diabetes induction caused significant hyperglycemia, dyslipidemia, hepatic and renal dysfunction, accompanied by marked gastric and ileal structural injury, including mucosal disruption, reduced glycoprotein content, and altered NT immunoreactivity. These changes were associated with increased oxidative stress, inflammatory activity, and disturbances in monoaminergic signaling. Functionally, diabetic rats exhibited impaired intestinal transit, reduced visceral sensory responses, and diminished cholinergic contractility in gastric and ileal smooth muscle. NT treatment significantly attenuated hyperglycemia, improved serum metabolic abnormalities, restored mucosal architecture, reduced oxidative stress, and improved gastrointestinal motility and contractile function. Most protective effects were abolished by SR-48692 co-administration, supporting a predominantly NTR1-dependent mechanism.
CONCLUSION: NT ameliorates diabetes-induced GI dysfunction and systemic metabolic disturbances primarily via NTR1 signaling, suggesting the NT/NTR1 axis as a potential therapeutic target for diabetic gastroenteropathy.